These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28258354)

  • 1. Basal markers and prognosis in luminal breast cancer.
    Engstrøm MJ; Valla M; Bofin AM
    Breast Cancer Res Treat; 2017 Jun; 163(2):207-217. PubMed ID: 28258354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
    Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
    Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer.
    Umekita Y; Ohi Y; Souda M; Rai Y; Sagara Y; Sagara Y; Tamada S; Tanimoto A
    Diagn Pathol; 2011 Apr; 6():36. PubMed ID: 21496280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
    Yu L; Yang WT; Cai X; Lu HF; Fan YZ; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
    Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
    Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women.
    Esnakula AK; Ricks-Santi L; Kwagyan J; Kanaan YM; DeWitty RL; Wilson LL; Gold B; Frederick WA; Naab TJ
    J Clin Pathol; 2014 Feb; 67(2):153-60. PubMed ID: 23986556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic features and prognostic significance of basal-like breast cancer].
    Liu H; Fan QH; Li X; Liu GZ
    Zhonghua Bing Li Xue Za Zhi; 2009 May; 38(5):316-22. PubMed ID: 19575874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand.
    Chuangsuwanich T; Pongpruttipan T; O-Charoenrat P; Komoltri C; Watcharahirun S; Sa-Nguanraksa D
    Asian Pac J Cancer Prev; 2014; 15(3):1187-92. PubMed ID: 24606439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
    Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
    Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
    J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
    Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
    Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.
    Bertaut A; Mounier M; Desmoulins I; Guiu S; Beltjens F; Darut-Jouve A; Ponnelle T; Arnould L; Arveux P
    Eur J Cancer Care (Engl); 2015 Nov; 24(6):920-8. PubMed ID: 25757548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.